

On Wednesday, 29 July 2015, 12:52, "eloder@bmj.com" <eloder@bmj.com> wrote:

29-Jul-2015

Dear Prof. Jureidini,

Manuscript ID BMJ.2014.022376.R4 entitled "Restoring Study 329: A randomised, controlled trial of the efficacy and harms of paroxetine and imipramine in the treatment of adolescent major depression"

I am returning this paper to you so that you can make revisions to it that incorporate the results of the independent check of AEs. Please return both a track changes and clean version of the manuscript.

Very truly yours,

Elizabeth Loder

https://mc.manuscriptcentral.com/bmj?URL_MASK=92b3a5030f6f4230b0db2397ca2d0bb4

1. Deadline: Your revised manuscript should be returned within one month.
2. Online and print publication: All original research in The BMJ is published with open access. The full text online version of your article, if accepted after revision, will be the indexed citable version (full details are at <http://resources.bmj.com/bmj/about-bmj/the-bmj-publishing-model>), while the print and iPad BMJ will carry an abridged version of your article, usually a few weeks afterwards. This abridged version of the article is essentially an evidence abstract called BMJ pico, which we would like you to write using a template and then email it to papersadmin@bmj.com (there are more details below on how to write this using a template). Publication of research on bmj.com is definitive and is not simply interim "epublication ahead of print", so if you do not wish to abridge your article using BMJ pico, you will be able to opt for online only publication. Please let us know if you would prefer this option.
If/when your article is accepted we will invite you to submit a video abstract, lasting no longer than 4 minutes, and based on the information in your paper's BMJ pico evidence abstract. The content and focus of the video must relate directly to the study that has been accepted for publication by The BMJ, and should not stray beyond the data.
3. Open access publication fee: The BMJ is committed to keeping research articles Open Access (with Creative Commons licences and deposit of the full text content in PubMedCentral as well as fully Open Access on bmj.com). To support this we are now asking all authors to pay an Open Access fee of £3000 on acceptance of their paper. If we accept your article we will ask you to pay the Open Access publication fee; we do have a waiver policy for authors who cannot pay. Consideration of your paper is not related to whether you can or cannot pay the fee (the editors will be unaware of this), and you need do nothing now.

4. How to submit your revised article: Log into <http://mc.manuscriptcentral.com/bmj> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

(Document Task not available)

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center. When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and Committee in the space provided. You can use this space to document any changes you make to the original manuscript and to explain your responses. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewer(s).

As well as submitting your revised manuscript, we also require a copy of the manuscript with changes highlighted. Please upload this as a supplemental file with file designation 'Revised Manuscript Marked copy'.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

IMPORTANT

When you revise and return your manuscript, please take note of all the following points about revising your article. Even if an item, such as a competing interests statement, was present and correct in the original draft of your paper, please check that it has not slipped out during revision.

- a. In your response to the reviewers and committee please provide, point by point, your replies to the comments made by the reviewers and the editors, and please explain how you have dealt with them in the paper. It may not be possible to respond in detail to all these points in the paper itself, so please do so in the box provided

- b. If your article is accepted it will then be edited, proofed, and - after your approval - published on bmj.com with open access. This open access Online First article will not be a pre-print. It will represent the full, citable, publication of that article. The citation will be year, volume, elocator (a unique identifier for that article): eg BMJ 2008;337:a145 — and this is what will appear immediately in Medline, PubMed, and other bibliographical indexes. We will give this citation in print and online, and you will need to use it when

you cite your article.

c. Please write an abridged version of the article for the print and iPad BMJ using the appropriate BMJ pico template for your study's design. Please be reassured that it doesn't take long to complete this. When your BMJ pico is ready please email it to papersadmin@bmjgroup.com. The templates for you to download are at <http://resources.bmj.com/bmj/authors/bmj-pico>

d. Please include these items in the revised manuscript to comply with BMJ style:

Title: this should include the study design eg "systematic review and meta-analysis"

Abstract

structured abstract including key summary statistics, as explained below (also see <http://resources.bmj.com/bmj/authors/types-of-article/research>) for every clinical trial - and for any other registered study - the study registration number and name of register – in the last line of the structured abstract.

Introduction

this should cover no more than three paragraphs, focusing on the research question and your reasons for asking it now

Methods:

for an intervention study the manuscript should include enough information about the intervention(s) and comparator(s) (even if this was usual care) for reviewers and readers to understand fully what happened in the study. To enable readers to replicate your work or implement the interventions in their own practice please also provide (uploaded as one or more supplemental files, including video and audio files where appropriate) any relevant detailed descriptions and materials. Alternatively, please provide in the manuscript urls to openly accessible websites where these materials can be found

Results

please report statistical aspects of the study in line with the Statistical Analyses and Methods in the Published Literature (SAMPL) guidelines <http://www.equator-network.org/reporting-guidelines/sampl/>

summary statistics to clarify your message. Please include in the results section of your structured abstract (and, of course, in the article's results section) the following terms, as appropriate:

For a clinical trial:

- Absolute event rates among experimental and control groups
- RRR (relative risk reduction)
- NNT or NNH (number needed to treat or harm) and its 95% confidence interval (or, if the trial is of a public health intervention, number helped per 1000 or 100,000)

For a cohort study:

- Absolute event rates over time (eg 10 years) among exposed and non-exposed groups
- RRR (relative risk reduction)

For a case control study:

- OR (odds ratio) for strength of association between exposure and outcome

For a study of a diagnostic test:

- Sensitivity and specificity
- PPV and NPV (positive and negative predictive values)

one or more references for the statistical package(s) used to analyse the data, eg RevMan for a systematic review. There is no need to provide a formal reference for a very widely used package that will be very familiar to general readers eg STATA, but please say in the text which version you used

for articles that include explicit statements of the quality of evidence and strength of recommendations, we prefer reporting using the GRADE system

Discussion

please write the discussion section of your paper in a structured way, to minimise the risk of careful explanation giving way to polemic. Please follow this structure:

statement of principal findings of the study

strengths and weaknesses of the study

strengths and weaknesses in relation to other studies, discussing important differences in results and what your study adds. Whenever possible please discuss your study in the light of relevant systematic reviews and meta-analyses (eg Cochrane reviews)

meaning of the study: possible explanations and implications for clinicians and

policymakers and other researchers; how your study could promote better decisions

unanswered questions and future research

Footnotes and statements

What this paper adds/what is already known box (as described at

<http://resources.bmj.com/bmj/authors/types-of-article/research>)

ID of ethics committee approval and name of the ethics committee/IRB; or a statement that approval was not required (see <http://resources.bmj.com/bmj/authors/editorial-policies/guidelines>) and a statement that participants gave informed consent before taking part

a statement that any identifiable patients have provided their signed consent to publication. Please submit, as a supplemental file, the signed BMJ patient consent form giving consent to publication in The BMJ of any information about identifiable individual patients. Publication of any personal information about a patient in The BMJ, for example in a case report or clinical photograph, will normally require the signed consent of the patient.

competing interests statement (see <http://resources.bmj.com/bmj/authors/editorial-policies/competing-interests>)

contributorship statement+ guarantor (see <http://resources.bmj.com/bmj/authors/article-submission/authorship-contributorship>)

transparency statement: a statement that the lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies are disclosed.

copyright statement/ licence for publication (see <http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse>)

signed patient consent form(s), if the article gives enough personal information about any patient(s): this sometimes occurs even in research papers - for example in a table giving demographic and clinical information about a small subgroup in a trial or observational study, or in quotes/tables in a qualitative study - (see http://resources.bmj.com/bmj/authors/editorial-policies/copy_of_patient-confidentiality)

a data sharing statement declaring what further information and data you are willing to make available, over and above the results reported in the paper. Suggested wording: "Data sharing: technical appendix, statistical code, and dataset [state whether any patient level data have been anonymised] are available at this repository or website OR from the corresponding author at ". If there are no such further data available, please use this wording: "Data sharing: no additional data available". For papers reporting the main results of trials of drugs or devices we require that the authors state, at a minimum, that the relevant anonymised patient level data are available on reasonable request from the authors

The BMJ has partnered with the Dryad Digital Repository datadryad.org to make open deposition easy and to allow direct linkage by doi from the dataset to The BMJ article and back - we encourage authors to use this option

funding statement (see <http://resources.bmj.com/bmj/authors/article-submission/article-requirements>)

statement of the independence of researchers from funders (see <http://resources.bmj.com/bmj/authors/article-submission/article-requirements>)

for studies funded or sponsored by industry (see <http://resources.bmj.com/bmj/authors/article-submission/article-requirements>)

a statement describing the role of the study sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication

assurance, in the cover letter, that a clinical trial funded by a pharmaceutical or other commercial company follows the guidelines on good publication practice (see <http://resources.bmj.com/bmj/authors/article-submission/article-requirements>)

inclusion in the list of contributors the name(s) any professional medical writer(s), specifying in the formal funding statement for the article who paid the writer. Writers and authors must have access to relevant data while writing articles.

Patient centred research

for studies that are relevant to patients we expect authors to report in their articles the extent of their study's patient-centredness, as highlighted by these questions:

did you involve patients/service users/carers/lay people in the design of this study?

Please state whether you did, and give details (Methods section)

was the development and/or selection of outcome measures informed by patients' priorities and experiences? Please give details (Methods section)

were patients/service users/carers/lay people involved in developing plans for participant recruitment and study conduct? If so, please specify how (Methods section)

have you planned to disseminate the results of the study to participants? If so how will

this be done? (Describe in brief footnote)

are patients thanked in the contributorship statement or acknowledgements?

for articles reporting randomised controlled trials: did you assess the burden of the intervention on patients' quality of life and health? If so, what evaluation method did you use, and what did you find? (Methods and Results sections)

(Document not available)